GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, suggesting detection bias was behind the increased cancer diagnosis rate ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

EA stock is spiraling Thursday after video game maker Electronic Arts released preliminary quarterly numbers and lowered its full-year bookings guidance.

The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction. This severe reaction can occur at any ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Listeria infection, otherwise known as listeriosis, is the third leading cause of death from foodborne illness in the U.S.

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.